Emilio Attolini

Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization cancer immunotherapies, cell therapies and cell-based biotherapeutics. Our goal is to support the development of novel cancer immunotherapies by accelerating the R&D, advancing the quality control and monitoring the clinical response to these treatments. Through the use of proprietary microfluidic technologies, highly-automated analytical instruments and AI-powered image and data analytics, the Cellply platform defines the function of the immune system one cell at a time, combining functional data with other multiplex data and providing an unprecedented single-cell analytical solution.

Pregmune is revolutionizing fertility care by applying artificial intelligence, data science and reproductive immunology to identify often-overlooked causes of infertility. Our introductory product, IRMA, is a comprehensive evaluation of blood markers and genetic traits found in scientific studies to contribute to implantation failure, miscarriage, or pregnancy complications. Some tests (histocompatibility and chromosome analysis) involve both parents when a partner or sperm donor is available for testing. Additional tests check the patient for signs of an autoimmune condition or high inflammation levels, as well as assess the patient’s thyroid, metabolism, thrombophilia risk, nutrition status, and hormones. The IRMA report includes a detailed analysis of test results, an AI-generated estimate of the likelihood that the patient and their partner or sperm donor will have a successful pregnancy while following our recommendations, and a personalized treatment plan. IRMAs proprietary artificial intelligence model analyzes more than fifty different attributes including patient history, laboratory test results and patient demographics. At Pregmune, we’re using science, technology and expertise to provide answers, recommend treatment, and help patients on their path to reproductive success.

Cardiolyse is a cloud ECG & HRV analytics platform, that enables real-time remote heart health monitoring, providing plain personalized reports, detection and up to two months data-based prognosis on dangerous heart events. Our groundbreaking ECG analytic technology enables people 45+, their families, healthcare providers and insurance companies: - To get in-depth snapshot of cardiovascular system state and to monitor its trend; - Allows making six-month forecast of serious cardiovascular events; - To learn how current lifestyle is interconnected with heart conditions.

ChestPal Pro helps frontline healthcare providers to reliably detect crackles and wheezes - aiding diagnosis and patient management.

AeroDron è un’azienda italiana esclusivamente dedicata alla ricerca e sviluppo di applicazioni che utilizzano Sistemi Aeromobili a Pilotaggio Remoto (SAPR). Dal 2013, anno della fondazione, AeroDron sperimenta e realizza soluzioni applicative in molteplici settori industriali e nella Pubblica Amministrazione, facendo leva sull’immenso valore delle informazioni che possono essere tratte da rilievi aerei a bassa quota, utilizzando lo stato dell’arte delle tecnologie di volo, rilevamento, visione e post-elaborazione. A sottolineare il nostro impegno all’innovazione nello sviluppo di applicazioni che utilizzino SAPR, AeroDron è stata selezionata come una delle più interessanti start-up dai principali interlocutori economici italiani e ha vinto il premio Lamarck a SMAU Bologna nel 2015. Nello 2013 siamo stati selezionati da b-ventures, un incubatore di Buongiorno e NTT DOCOMO, tra le start-up da sostenere attraverso un programma di accelerazione costruito specificatamente per le iniziative nei settori ad alta tecnologia. Grazie a b-ventrues, AeroDron ha potuto attrarre nella propria compagine societaria una selezione di investitori e partner di primaria importanza, che hanno garantito al nostro progetto le risorse e il mentoring indispensabili per supportare la visione e il nostro progetto strategico. La nostra missione è acquisire la leadership nella realizzazione di soluzioni applicative e nella fornitura di servizi di qualità basati sull’utilizzo dei SAPR. Specializzati in geomatica, interpretazione delle immagini, modellazione 3D e remote sensing, mettiamo a disposizione le nostre competenze per il monitoraggio ambientale, la gestione del rischio idrogeologico, l’agricoltura di precisione, la progettazione, le ispezioni infrastrutturali, la topografia e in tutte quelle occasioni in cui l’utilizzo di SAPR può creare valore, migliorare l’efficacia e mitigare i rischi dei nostri Clienti e della Comunità.

Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization cancer immunotherapies, cell therapies and cell-based biotherapeutics. Our goal is to support the development of novel cancer immunotherapies by accelerating the R&D, advancing the quality control and monitoring the clinical response to these treatments. Through the use of proprietary microfluidic technologies, highly-automated analytical instruments and AI-powered image and data analytics, the Cellply platform defines the function of the immune system one cell at a time, combining functional data with other multiplex data and providing an unprecedented single-cell analytical solution.

Pregmune is revolutionizing fertility care by applying artificial intelligence, data science and reproductive immunology to identify often-overlooked causes of infertility. Our introductory product, IRMA, is a comprehensive evaluation of blood markers and genetic traits found in scientific studies to contribute to implantation failure, miscarriage, or pregnancy complications. Some tests (histocompatibility and chromosome analysis) involve both parents when a partner or sperm donor is available for testing. Additional tests check the patient for signs of an autoimmune condition or high inflammation levels, as well as assess the patient’s thyroid, metabolism, thrombophilia risk, nutrition status, and hormones. The IRMA report includes a detailed analysis of test results, an AI-generated estimate of the likelihood that the patient and their partner or sperm donor will have a successful pregnancy while following our recommendations, and a personalized treatment plan. IRMAs proprietary artificial intelligence model analyzes more than fifty different attributes including patient history, laboratory test results and patient demographics. At Pregmune, we’re using science, technology and expertise to provide answers, recommend treatment, and help patients on their path to reproductive success.

Cardiolyse is a cloud ECG & HRV analytics platform, that enables real-time remote heart health monitoring, providing plain personalized reports, detection and up to two months data-based prognosis on dangerous heart events. Our groundbreaking ECG analytic technology enables people 45+, their families, healthcare providers and insurance companies: - To get in-depth snapshot of cardiovascular system state and to monitor its trend; - Allows making six-month forecast of serious cardiovascular events; - To learn how current lifestyle is interconnected with heart conditions.

ChestPal Pro helps frontline healthcare providers to reliably detect crackles and wheezes - aiding diagnosis and patient management.